Country: United States

T1International Statement on Scientific Independence and the Freedom to Speak Without Fear

16 Jun 2026, 1:11 p.m. in Content Type: News & Statements, Country: United States by T1International's Federal Working Group

T1International's Federal Working Group issued this statement in response to clinicians being removed from the ADA's 85th Scientific Sessions after sharing a published editorial on science and public policy — an event that raised serious concerns about academic freedom and the ability of researchers to speak without fear of retaliation. As a pharma-free, patient-led organization, T1International holds that scientific independence is not abstract: when researchers self-censor or institutions suppress open dialogue, people with diabetes bear the consequences through delayed progress and reduced transparency. T1International stands with researchers and clinicians who defend scientific integrity, and commits to continuing its history of speaking truth to power on behalf of the diabetes community. Read more

Patients Win: How #insulin4all Advocates Helped make insulin more affordable

6 Apr 2026, 3:07 p.m. in Content Type: News & Statements, Country: United States, Insulin Access: Price Caps by T1International

Insulin has long been unaffordable for many people in the United States, even though the cost to produce most insulin vials remains between $3 and $6. Over the past few decades, prices have skyrocketed, with “the Big Three” insulin manufacturers, Eli Lilly, Novo Nordisk, and Sanofi, controlling nearly all of the U.S. insulin market and raising prices in lockstep. Thanks to persistent advocacy and legal action, we have won a significant victory in holding intermediaries accountable for practices that drove up insulin costs.
Read more

A Trillion-Dollar Company and a $687 Vial: My Conversation with Eli Lilly

12 Jan 2026, 8:02 p.m. in Content Type: Advocacy Stories, Country: United States, Insulin Access: Price Caps by Molly King

This blog is a personal story from Molly King, a person living with type 1 diabetes and T1International’s Indiana #insulin4all Chapter co-lead. Molly reflects on her experience rationing insulin and being hospitalized, and she describes a recent conversation with an Eli Lilly executive about insulin pricing. Her story highlights the ongoing reality of insulin rationing, the impact of high list prices, and why T1International remains independent from pharmaceutical company funding while advocating for affordable insulin for everyone, everywhere. Read more

World Diabetes Day 2025: Advocates stand together for Access, Affordability, and Action

16 Nov 2025, 7:39 p.m. in Action & Workshop, Country: Democratic Republic of Congo, Country: Egypt, Country: France, Country: Global, Country: Nigeria, Country: Pakistan, Country: Sierra Leone, Country: South Africa, Country: United States, Insulin Access: Price Caps, Taking on Monopoly Power: Public Pharma, The Right to Full Care: Combatting Discrimination with Education, The Right to Full Care: Glucose Self-Monitoring Supplies, The Right to Full Care: Other Essential Medicine Access & Universal Health Coverage by T1International

On November 14th, 2025, World Diabetes Day, #insulin4all advocates across the globe came together to make a demand: that they be able to access and afford their life-sustaining medications. Recent data showed that 1 in 3 people around the world rationed their insulin due to cost in 2024. At T1International, we know that #insulin4all is a reasonable and dignified demand– and yet, we are still too far from achieving a reality where everyone, no matter where they live, has access to the medicine and supplies they need to survive and flourish. Read more

New $55 Insulin Pens Mark Step in California’s Fight Against Insulin Price Gouging

7 Oct 2025, 10:40 p.m. in Content Type: News & Statements, Country: United States, Taking on Monopoly Power: Public Pharma by T1International

The state of California will take significant steps forward to increase insulin access and affordability – beginning January 1, 2026, CalRx will offer a box of five insulin pens for $55 to anyone who needs it. California announced that Civica will contract with India-based biosimilar manufacturer Biocon to fulfill its commitment to bring low-cost insulin glargine (a long-acting and not name-brand insulin) to California through the CalRx label. Read more

Fixing a Broken System: The Path to Public Pharma in New York

6 Oct 2025, 11 p.m. in Action & Workshop, Contains: Resource, Country: United States, Taking on Monopoly Power: Public Pharma by T1International

On Thursday, September 25, 2025, T1International brought policy leaders, advocates, and patients together at NYU Law for “Fixing a Broken System: The Path to Public Pharma in New York,” a major public event highlighting the urgent need for publicly controlled pharmaceutical production to counter skyrocketing drug prices. Read more

T1International statement regarding largest cuts to healthcare coverage in American History.

3 Jul 2025, 8:45 p.m. in Content Type: News & Statements, Country: United States, The Right to Full Care: Other Essential Medicine Access & Universal Health Coverage by T1International

The recently passed “One Big Beautiful Bill” represents the largest and greatest healthcare loss in American history, cutting health care for 17 million people living in this country. This bill, passed in the United States Congress today, is a profound and deadly cut for people living with diabetes, their families, and marginalized and disabled people across the country.
Read more

"I Wasn’t a ‘Bad Diabetic.’ I Just Couldn’t Afford Insulin."

11 Jun 2025, 5:06 p.m. in Content Type: Advocacy Stories, Country: United States, Taking on Monopoly Power: Patent Reform by Lacy McGee

Findings from T1International's 2024 Out-of-Pocket Expenses and Rationing Survey

28 May 2025, 4:15 p.m. in Contains: Resource, Content Type: News & Statements, Country: Panama, Country: United States, Research by T1International

U.S. Action 2025: Circus of Pharma Greed!

3 Feb 2025, 11:58 p.m. in Action & Workshop, Content Type: News & Statements, Country: United States, Taking on Monopoly Power: Patent Reform by T1International